TRUSCREEN GROUP LIMITED — Earnings Release 2026

Apr 27, 2026

NZX/ASX Announcement

truscreen
a world without
cervical cancer

28 April 2026

FY31 March 2026 Revenue and Results Guidance Achieved

Truscreen Group Limited (NZX/ASX: TRU) (TruScreen or the Company), a global provider of AI-enabled cervical cancer screening technology confirms the unaudited revenue and earnings guidance for the financial year ending 31 March 2026 (FY2026), previously provided on 26 February 2026.

FY2026 revenue guidance

• Unaudited FY2026 product sales revenue was in line with the guidance provided on 26 February 2026 at approximately NZ$2.4 million, representing an increase of 41% on FY2025.
• Total unaudited revenue for FY2026 is expected to be approximately NZ$2.8 million, slightly higher than the previous guidance and an increase of around 29% on FY2025.

FY2026 Earnings guidance

• The Company is expected to report an unaudited loss for FY2026 similar to FY2025 being a loss of ~NZ$2.2 million, reflecting additional market access development costs.
• During FY2026, TruScreen has invested in expanding its distributor network and market presence in Uzbekistan, India, Indonesia and selected African markets. These investments are important to build the critical mass of product adoption and market access required to support the Company's path to sustainable profitability over the medium term. This is evidenced by revenue spread across a wider number of countries in the current year. The February 2026 publication of the peer reviewed results by Germany's BMC Cancer of the circa 15,000 patients over 4 years clinical study by COGA (Chinese Obstetricians and Gynaecologists Association) has provided positive interest in our AI enabled TruScreen technology.
• With the positive interest and TruScreen's ongoing success with the National Aids Council cervical cancer screening programme in Zimbabwe, TruScreen was invited by global and national aid agencies to be part of a consortium and submitted three applications to UNITAID for funding to assist in the achievement of WHO's 2030 cervical cancer 90-70-90 milestone goals (see note below). Funding for these programmes will be up to US$57.3 million over the three-year period with potential revenue for TruScreen as a consortium lead of up to US$18.4 million. Successful applicants for these programmes will be advised on or around November 2026.

This announcement has been approved for release by the Board of TruScreen Group Limited.

Note

World Health Organisation's 2030 90-70-90 milestones

• vaccination: 90% of girls fully vaccinated with the HPV vaccine by the age of 15;
• screening: 70% of women screened using a high-performance test by the age of 35, and again by the age of 45;
• treatment: 90% of women with pre-cancer treated and 90% of women with invasive cancer managed.

Ends

---

truscreen
a world without
cervical cancer

For more information, visit www.truscreen.com or contact:

Tony Ho
Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Jack Zhang
Media & Investor Relations
jack@sparkplus.org

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

To learn more, please visit: www.truscreen.com/.

*Based on Single Use Sensor sales.